Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Myotome adaptability confers developmental robustness to somitic myogenesis in response to fibre number alteration.

Roy SD, Williams VC, Pipalia TG, Li K, Hammond CL, Knappe S, Knight RD, Hughes SM.

Dev Biol. 2017 Nov 15;431(2):321-335. doi: 10.1016/j.ydbio.2017.08.029. Epub 2017 Sep 5.

2.

CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.

Leonard JP, Gregory SA, Smith H, Horner TJ, Williams VC, Giampietro P, Lin TS.

Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):191-6. doi: 10.1016/j.clml.2015.12.011. Epub 2016 Jan 4.

PMID:
26832194
3.

Long-term follow-up of previously treated and treatment-naïve patients who received tositumomab and I-131 tositumomab.

Horner TJ, Williams VC, Giampietro P, Witman PA, Lin TS.

Leuk Lymphoma. 2016 May;57(5):1238-40. doi: 10.3109/10428194.2015.1082179. Epub 2015 Dec 23. No abstract available.

PMID:
26696131
4.

Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab.

Quackenbush RC, Horner TJ, Williams VC, Giampietro P, Lin TS.

Leuk Lymphoma. 2015 Mar;56(3):779-81. doi: 10.3109/10428194.2014.927461. Epub 2014 Jul 23. No abstract available.

PMID:
24898665
5.

eIF4EBP3L acts as a gatekeeper of TORC1 in activity-dependent muscle growth by specifically regulating Mef2ca translational initiation.

Yogev O, Williams VC, Hinits Y, Hughes SM.

PLoS Biol. 2013 Oct;11(10):e1001679. doi: 10.1371/journal.pbio.1001679. Epub 2013 Oct 15.

6.

Oesophageal and sternohyal muscle fibres are novel Pax3-dependent migratory somite derivatives essential for ingestion.

Minchin JE, Williams VC, Hinits Y, Low S, Tandon P, Fan CM, Rawls JF, Hughes SM.

Development. 2013 Jul;140(14):2972-84. doi: 10.1242/dev.090050. Epub 2013 Jun 12. Erratum in: Development. 2013 Oct;140(20):4296.

7.

Sonic hedgehog acts cell-autonomously on muscle precursor cells to generate limb muscle diversity.

Anderson C, Williams VC, Moyon B, Daubas P, Tajbakhsh S, Buckingham ME, Shiroishi T, Hughes SM, Borycki AG.

Genes Dev. 2012 Sep 15;26(18):2103-17. doi: 10.1101/gad.187807.112.

8.

Defective cranial skeletal development, larval lethality and haploinsufficiency in Myod mutant zebrafish.

Hinits Y, Williams VC, Sweetman D, Donn TM, Ma TP, Moens CB, Hughes SM.

Dev Biol. 2011 Oct 1;358(1):102-12. doi: 10.1016/j.ydbio.2011.07.015. Epub 2011 Jul 23.

9.

Cooperation between Shh and IGF-I in promoting myogenic proliferation and differentiation via the MAPK/ERK and PI3K/Akt pathways requires Smo activity.

Madhala-Levy D, Williams VC, Hughes SM, Reshef R, Halevy O.

J Cell Physiol. 2012 Apr;227(4):1455-64. doi: 10.1002/jcp.22861.

10.

Differential corticospinal tract degeneration in homozygous 'D90A' SOD-1 ALS and sporadic ALS.

Blain CR, Brunton S, Williams VC, Leemans A, Turner MR, Andersen PM, Catani M, Stanton BR, Ganesalingham J, Jones DK, Williams SC, Leigh PN, Simmons A.

J Neurol Neurosurg Psychiatry. 2011 Aug;82(8):843-9. doi: 10.1136/jnnp.2010.236018. Epub 2011 Apr 21.

11.

Diffusion tensor imaging in sporadic and familial (D90A SOD1) forms of amyotrophic lateral sclerosis.

Stanton BR, Shinhmar D, Turner MR, Williams VC, Williams SC, Blain CR, Giampietro VP, Catani M, Leigh PN, Andersen PM, Simmons A.

Arch Neurol. 2009 Jan;66(1):109-15. doi: 10.1001/archneurol.2008.527.

PMID:
19139308
12.

Neurofibromatosis type 1 revisited.

Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL.

Pediatrics. 2009 Jan;123(1):124-33. doi: 10.1542/peds.2007-3204. Review.

PMID:
19117870
13.

Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.

Cohen CJ, Kubota M, Brachman PS, Harley WB, Schneider S, Williams VC, Sutherland-Phillips DH, Lim ML, Balu RB, Shaefer MS; Abacavir-Lamivudine Once-Daily HIV Assessment (ALOHA) Study Group.

Pharmacotherapy. 2008 Mar;28(3):314-22. doi: 10.1592/phco.28.3.314.

PMID:
18294111
14.

Evidence-based versus reported epilepsy management practices.

Mastriani KS, Williams VC, Hulsey TC, Wheless JW, Maria BL.

J Child Neurol. 2008 May;23(5):507-14. doi: 10.1177/0883073807309785. Epub 2008 Feb 15.

PMID:
18281618
15.

A longitudinal study of diffusion tensor MRI in ALS.

Blain CR, Williams VC, Johnston C, Stanton BR, Ganesalingam J, Jarosz JM, Jones DK, Barker GJ, Williams SC, Leigh NP, Simmons A.

Amyotroph Lateral Scler. 2007 Dec;8(6):348-55. Epub 2007 Oct 8.

PMID:
17924235
16.

Cortical activation during motor imagery is reduced in Amyotrophic Lateral Sclerosis.

Stanton BR, Williams VC, Leigh PN, Williams SC, Blain CR, Giampietro VP, Simmons A.

Brain Res. 2007 Oct 3;1172:145-51. Epub 2007 Aug 3.

PMID:
17765211
17.

Spinal muscular atrophy: classification, diagnosis, management, pathogenesis, and future research directions.

Kostova FV, Williams VC, Heemskerk J, Iannaccone S, Didonato C, Swoboda K, Maria BL.

J Child Neurol. 2007 Aug;22(8):926-45.

PMID:
17761647
18.

Acute disseminated encephalomyelitis following infectious mononucleosis.

Bahadori HR, Williams VC, Turner RP, Rumboldt Z, Reigart JR, Fowler SL, Chavis PS, Maria BL.

J Child Neurol. 2007 Mar;22(3):324-8.

PMID:
17621505
19.

Altered cortical activation during a motor task in ALS. Evidence for involvement of central pathways.

Stanton BR, Williams VC, Leigh PN, Williams SC, Blain CR, Jarosz JM, Simmons A.

J Neurol. 2007 Sep;254(9):1260-7. Epub 2007 Mar 25.

PMID:
17385077
20.

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team.

HIV Med. 2006 Mar;7(2):85-98.

21.

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, Wakeford JH, Snidow JW, Shachoy-Clark AD, Fleming JW, Pakes GE, Hernandez JE; ESS40003 Study Team.

BMC Infect Dis. 2005 Jan 12;5:2.

22.

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.

McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE, Ross LL.

AIDS. 2005 Jan 3;19(1):15-23.

PMID:
15627029
23.

Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.

Lonergan JT, McComsey GA, Fisher RL, Shalit P, File TM Jr, Ward DJ, Williams VC, Hessenthaler SM, Lindsey L, Hernandez JE; ESS40010 (TARHEEL) Study Team.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):935-42.

PMID:
15220700
24.

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.

McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE; Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team.

Clin Infect Dis. 2004 Jan 15;38(2):263-70. Epub 2003 Dec 18.

PMID:
14699460
25.

Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.

Fischl MA, Burnside AE Jr, Farthing CE, Thompson MA, Bellos NC, Williams VC, Kauf TL, Wannamaker PG, Shaefer MS; ESS40005 Study Team.

Pharmacotherapy. 2003 Nov;23(11):1432-40.

PMID:
14620390
26.

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

Rawlings MK, Thompson MA, Farthing CF, Brown LS, Racine J, Scott RC, Crawford KH, Goodwin SD, Tolson JM, Williams VC, Shaefer MS; NZTA4006 Helping to Enhance Adherence to Antiretroviral Therapy (HEART) Study Team.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):174-83.

PMID:
14526206
28.

Uranium(VI) sulfilimine complexes: a new class of nitrogen analogues of the uranyl ion.

Williams VC, Müller M, Leech MA, Denning RG, Green ML.

Inorg Chem. 2000 Jun 12;39(12):2538-41.

PMID:
11197007
29.

Activation of

Williams VC, Dai C, Li Z, Collins S, Piers WE, Clegg W, Elsegood MR, Marder TB.

Angew Chem Int Ed Engl. 1999 Dec 16;38(24):3695-3698.

PMID:
10649328
30.

Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.

Schwartz JI, Margolskee DJ, Bjornsson TD, Williams VC, Hsieh JY, Lin CC, Rogers JD.

Br J Clin Pharmacol. 1993 Nov;36(5):464-6.

31.

The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

Dahlén B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, Zetterström O, Dahlén SE.

Eur Respir J. 1993 Jul;6(7):1018-26.

PMID:
8396534
32.

Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.

Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW.

Am Rev Respir Dis. 1992 Aug;146(2):358-63.

PMID:
1489125
33.

Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma.

Rasmussen JB, Eriksson LO, Margolskee DJ, Tagari P, Williams VC, Andersson KE.

J Allergy Clin Immunol. 1992 Aug;90(2):193-201.

PMID:
1323587
34.

Effect of an oral alpha 2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus.

Ortiz-Alonso FJ, Herman WH, Gertz BJ, Williams VC, Smith MJ, Halter JB.

Metabolism. 1991 Nov;40(11):1160-7.

35.

Leukotriene (LT) D4 is involved in antigen-induced asthma: a study with the LTD4 receptor antagonist, MK-571.

Rasmussen JB, Margolskee DJ, Eriksson LO, Williams VC, Andersson KE.

Ann N Y Acad Sci. 1991;629:436. No abstract available.

PMID:
1952571
36.

Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.

Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM.

N Engl J Med. 1990 Dec 20;323(25):1736-9.

37.

Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.

Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Gettys TW, Taylor IL, Rushakoff RJ, Williams VC, Coker LD.

J Clin Endocrinol Metab. 1990 May;70(5):1312-8.

PMID:
2186058
38.

Inhibition of norfloxacin absorption by antacids.

Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A.

Antimicrob Agents Chemother. 1990 Mar;34(3):432-5.

39.

Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine.

Warren JB, Dollery CT, Fuller RW, Williams VC, Gertz BJ.

Clin Pharmacol Ther. 1989 Jul;46(1):103-9.

PMID:
2568210
40.

The elements of effective salary administration programs.

McMillan JD, Williams VC.

Pers J. 1982 Nov;61(11):832-8. No abstract available.

PMID:
10258018
41.

How to recover expenses and charge patients equitably.

Williams VC.

Hospitals. 1977 Jun 1;51(11):91-2, 94. No abstract available.

PMID:
863437
42.

Phase equilibrium description.

WILLIAMS VC.

J Phys Colloid Chem. 1948 Oct;52(7):1263. No abstract available.

PMID:
18886190
43.

Bellows type heat capacity calorimeter.

WILLIAMS VC, SIVETZ M.

Rev Sci Instrum. 1946 Feb;17:71. No abstract available.

PMID:
21016875

Supplemental Content

Loading ...
Support Center